We also provide compelling evidence that the transcription factor SNAI2, in conjunction with MEK1/2 signaling, drives the hybrid EMT phenotype in TPM cancers, facilitating survival and apoptosis resistance through epigenetic suppression of apoptotic markers like BIM and BMF. The gene discussed is MAP2K1; the disease is cancer.